Last reviewed · How we verify
NCT05427864
Comparison of Multiparametric Prostate MRI and Ga-68 PSMA PET Imaging in Prostate Cancer Staging
NA trial testing Multiparametric Prostate MRI in Prostate Cancer in 47 participants. Status unknown.
5 January 2023
Quick facts
| Lead sponsor | Gulhane Training and Research Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 47 |
| Start date | 1 January 2020 |
| Primary completion | 5 January 2023 |
| Estimated completion | 5 March 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Multiparametric Prostate MRI
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Prostate Cancer Stage — all drugs for Prostate Cancer Stage →
Sponsor
Gulhane Training and Research Hospital
Who can join
Eligibility, male only, with Prostate Cancer or Prostate Cancer Stage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, it is aimed to compare the lesion location, lesion size, local and distant metastases detection rates of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer. The pathologies of the patients who were decided to undergo radical prostatectomy as a treatment will also be compared with the staging tests.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05427864
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Gulhane Training and Research Hospital trials
Trials by the same sponsor.
- NCT07283588 — İntensive Care Sepsis Prevelance in Turkey (INSEP-TURK) · active not recruiting
- NCT07145554 — f-ESWT vs Steroid Injection for Piriformis Syndrome · NA · completed
- NCT07039370 — Molecular Signatures of TMS Response in Treatment-Resistant Depression · NA · recruiting
- NCT06995222 — The Role of Renal Resistive Index (RI) in Predicting Acute Kidney Injury Progression in Intensive Care Clinic · recruiting
- NCT06765031 — The Role of Furosemide Stress Test in the Intensive Care Clinic · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05427864 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gulhane Training and Research Hospital
- Last refreshed: 28 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05427864.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing